Daytrading, Eminis, Forex trading, Swing Trading BREAKING NEWS - 479357
Ronaldinho  |  by www.tradingmarkets.com. All rights reserved. 7.11 | 8:43

Receive Dave's best setups each evening from his favorite trading patterns.

Let Gary Kaltbaum send you timely emails to alrt when breakouts occure.
Every day receive the best plan of attack for the next day's trading directly from professional trader Kevin Haggerty.

(RTTNews) - Tuesday afternoon, Clinical Data, Inc. ( | | | ), a company that provides comprehensive molecular and pharmacogenomics services as well as genetic tests to improve patient care, revealed that it has entered into an agreement with Mayo Foundation for Medical Education and Research or Mayo Clinic granting the company, a license under a variety of patents and patent applications to provide testing of the UGT1A1 gene. The company also revealed that it has exclusively licensed to Mayo Clinic certain of its own UGT1A1-related patent rights.

The Newton headquartered Massachusetts based Scientific and Technical Instruments company said that UGT1A1 gene is involved in the metabolism of irinotecan or Camptosar, a common first-line treatment for advanced colo-rectal cancer. Despite being effective, irinotecan can cause lethal reactions in a considerable number of patients due to its inability to metabolize the drug in a proper fashion. The FDA had recently revised the labeling for Camptosar to recommend reduced dosing in patients who test homozygous for the 28 variant of UGT1A1.

Clinical Data observed that after the agreement with Mayo, the company has joined a select group of laboratories to offer a pharmacogenomic test for UGT1A1*28. Also, the company noted that by out-licensing its own UGT1A1-related IP to Mayo Clinic, the company has enabled Mayo to continue further development of assays addressing this important pathway. CLDA is currently trading at $14.

79 flat with the previous close on a volume of 8,360 shares.

Read more on by www.tradingmarkets.com. All rights reserved.
Keywords: Mayo Clinic
Related news
Post comments
Name
Place
9 + 1 =
Comments